About us

Reccura Therapeutics AS is a Norwegian subsidiary company to the Swedish biotechnology company Coegin Pharma AB as part of Coegin Pharma AB’s hub & spoke “portfolio” biotech model, with clear benefits to investors.
 
Reccura Therapeutics AS will develop the promising novel and proprietary drug candidate AVX001 further, and will primarily be financed separately from Coegin Pharma AB.

Contact

Jens Eriksson, acting CEO Coegin Pharma AB
info@coeginpharma.com